Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.  In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free survival (EFS) (a secondary endpoint) were observed in patients treated with volasertib in combination with low-dose cytarabine (LDAC) compared to patients treated with LDAC alone. Presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, Ga., these results support the initiation of a Phase III study of volasertib in combination with LDAC expected to start in early 2013. 

AML is one of the most common types of leukemia in adults.2  A common treatment approach is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy.3,4  However, many patients over 65 years of age – whose prognosis is typically poor5 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time.3,4 

The open-label study enrolled 87 adult patients randomly assigned to receive either volasertib in combination with LDAC (n=42) or LDAC alone (n=45).   The primary endpoint was objective response (complete remission [CR] or CR with incomplete blood count recovery [CRi]).  Objective responses were observed in 31 percent of patients (13 of 42 patients) treated with the combination of volasertib plus LDAC compared with 13.3 percent of the patients (6 of 45 patients) treated with LDAC alone (odds ratio: 2.91; p = 0.0523).  The median (range) time to remission was 71 (2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... stimulants combined provide greater improvement in symptoms ... Addrenex Pharmaceuticals, Inc. today announced positive results ... Clonicel demonstrating that the combination of Clonicel ... in attention deficit hyperactivity disorder (ADHD) symptoms ...
... After a review of several vendors, the University ... selected the services of Velos and its flagship product, ... implemented at UCLA,s Jonsson Comprehensive Cancer Center and an ... Plans are in place to deploy the system in ...
Cached Medicine Technology:Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:8/29/2014)... yoga month was created by the Yoga Health Foundation ... To support this Ekhart Yoga is offering those interested ... This 4 week guided online yoga program is especially ... regularly from their own home. Led by Esther Ekhart, ... all levels, and the dynamic classes will help build ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Senior ... of operations & business development. , Rees has been ... president of business development. , A wholly owned subsidiary ... Independence provides older adults with options, including personalized home ... care (e.g., meal preparation) and therapeutic adult day centers. ...
(Date:8/29/2014)... University of Houston Graduate College of Social Work is the ... million grant from the National Institute of Drug Abuse (NIDA) ... long-term use and health consequences of heroin use. Additionally, the ... future research endeavors. , Heroin use has increased ... prescription pain medication abuse to the cheaper and more available ...
(Date:8/29/2014)... 2014 Last week, the Fed reported ... monthly gain. Industrial production rose to 0.4% while manufacturing output ... is the single largest boost since February this year. Capacity ... since February as well – an increase that could be ... to a 79.2% rate, which is a measure of slack ...
(Date:8/29/2014)... R.I. (PRWEB) August 29, 2014 A home should ... crop up if unaddressed. That’s why Amica Insurance is sharing some ... National Safety Council suggests taking the following safety measures: , Kitchen, ... disinfectants – in their original containers, and keep them away from ... a wall bracket near an exit. , Bathroom , ...
Breaking Medicine News(10 mins):Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Improve Home Safety with Tips from Amica Insurance 2
... Over Estimated,A UK doctor, and a leading expert warned ... are being overstated, leading to unnecessary panic. // ... Tyne said there was very little evidence suggesting that ... nut allergies had saved lives. ,Writing in ...
... A team from the Medical Research Council suggests that ... triggered by the presence of a hormone in semen.// ... the development of tumors. ,In a report in ... recommend that women having either cancer should ask their ...
... night’s sleep is critical to doing well in school because ... in class and while doing homework.// While this is common ... can be complex; and the rewards for treatment can extend ... be getting a good night’s sleep is that he or ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... emergency unit is said to make patients wait longer than ... ,This news has only added salt to the ... procedures at the ERI following its branding as one of ... ,Recent figures have shown that more than a third of ...
... government today introduced a controversial licensing scheme. According to ... will be permitted to describe the ailments they claim ... aim to bring homeopathic remedies into the area of ... doctors and scientists believe that products with no scientific ...
Cached Medicine News:Health News:Inordinately Long Waiting Times at A&E Infirmary 2Health News:Doctors worried about Homeopathic licensing 2
... be used only with the E3671 twisted snare ... the wing nut and the loop can be ... ratchet so that the loop can be slipped ... length - 5.6 inches. Comes with one package ...
Open 14 mm fixation ring with teeth to prevent damage to conjuctiva. Gauge is marked every 10 degrees to determine the extent of the arc to be incised. Two broad marks align with steep axis....
... Titanium. Designed to fixate the ... The two-sided ring can easily ... pointed or smooth side on ... pressure to the eye to ...
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Medicine Products: